NCT05463939Approved For Marketing不适用
Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient diagnosed with Relapsed or Refractory Multiple Myeloma
- •Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial
排除标准
- 未提供
研究者
相似试验
Approved For Marketing
不适用
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USASmall Cell Lung CancerNCT04291937Jazz Pharmaceuticals
Approved For Marketing
不适用
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaCarcinoma, Renal CellNCT00130897Pfizer
Approved For Marketing
不适用
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung CancerMyelosuppression AdultChemotherapeutic ToxicitySmall Cell Lung CancerNCT04504513G1 Therapeutics, Inc.
Approved For Marketing
不适用
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCLDLBCLNCT04300803MorphoSys AG
Approved For Marketing
不适用
Expanded Access for Treatment With ImetelstatMyelodysplastic SyndromesNCT05937568Geron Corporation